"Advanced melanoma" trang 1 - tải miễn phí từ tailieuXANH
Safety, activity, and pharmacokinetics of camrelizumab in advanced Asian melanoma patients: A phase I study

Safety, activity, and pharmacokinetics of camrelizumab in advanced Asian melanoma patients: A phase I study
10    133    1
Comparative efficacy and safety of combination therapies for advanced melanoma: A network meta-analysis

Comparative efficacy and safety of combination therapies for advanced melanoma: A network meta-analysis
10    63    0
Early cost-effectiveness of tumor infiltrating lymphocytes (TIL) for second line treatment in advanced melanoma: A model-based economic evaluation

Early cost-effectiveness of tumor infiltrating lymphocytes (TIL) for second line treatment in advanced melanoma: A model-based economic evaluation
11    56    0
Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: The IMAGE study

Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: The IMAGE study
12    105    1
Báo cáo hóa học:

Báo cáo hóa học: "Multicenter phase II study of matured dendritic cells pulsed with melanoma cell line lysates in patients with advanced melanoma"
11    41    0
Vemurafenib in Chinese patients with BRAFV600 mutation–positive unresectable or metastatic melanoma: An open-label, multicenter phase I study

Vemurafenib in Chinese patients with BRAFV600 mutation–positive unresectable or metastatic melanoma: An open-label, multicenter phase I study
7    73    0
A phase II trial of recombinant MAGE-A3 protein with immunostimulant AS15 in combination with high-dose Interleukin-2 (HDIL2) induction therapy in metastatic melanoma

A phase II trial of recombinant MAGE-A3 protein with immunostimulant AS15 in combination with high-dose Interleukin-2 (HDIL2) induction therapy in metastatic melanoma
9    51    0
Ebook Dermatology for advanced practice clinicians (1st edition): Part 1

Ebook Dermatology for advanced practice clinicians (1st edition): Part 1
188    45    1
Early discontinuation of PD-1 blockade upon achieving a complete or partial response in patients with advanced melanoma: The multicentre prospective Safe Stop trial

Early discontinuation of PD-1 blockade upon achieving a complete or partial response in patients with advanced melanoma: The multicentre prospective Safe Stop trial
9    111    1
ADAS for the Car of the Future - Interface Concepts for Advanced Driver Assistant Systems in a Sustainable Mobility Concept of 2020

ADAS for the Car of the Future - Interface Concepts for Advanced Driver Assistant Systems in a Sustainable Mobility Concept of 2020
68    52    0
Risk factors for severe rash with use of vemurafenib alone or in combination with cobimetinib for advanced melanoma: Pooled analysis of clinical trials

Risk factors for severe rash with use of vemurafenib alone or in combination with cobimetinib for advanced melanoma: Pooled analysis of clinical trials
6    64    0
Severe colitis after PD-1 blockade with nivolumab in advanced melanoma patients: Potential role of Th1-dominant immune response in immune-related adverse events: Two case reports

Severe colitis after PD-1 blockade with nivolumab in advanced melanoma patients: Potential role of Th1-dominant immune response in immune-related adverse events: Two case reports
7    87    0
Ineffective anti PD-1 therapy after BRAF inhibitor failure in advanced melanoma

Ineffective anti PD-1 therapy after BRAF inhibitor failure in advanced melanoma
7    68    0
Evaluating different adoption scenarios for TIL-therapy and the influence on its (early) cost-effectiveness

Evaluating different adoption scenarios for TIL-therapy and the influence on its (early) cost-effectiveness
14    58    0
Association of advanced age and cancer history with autoimmune disease in melanoma patients: A cross-sectional study

Association of advanced age and cancer history with autoimmune disease in melanoma patients: A cross-sectional study
8    178    2
Đã phát hiện trình chặn quảng cáo AdBlock
Trang web này phụ thuộc vào doanh thu từ số lần hiển thị quảng cáo để tồn tại. Vui lòng tắt trình chặn quảng cáo của bạn hoặc tạm dừng tính năng chặn quảng cáo cho trang web này.